about
Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagusPerioperative chemotherapy versus primary surgery for locoregionally advanced resectable adenocarcinoma of the stomach, gastroesophageal junction and lower esophagusNovel CD9-targeted therapies in gastric cancerTelomeres and telomere dynamics: relevance to cancers of the GI tractEvaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer.A Pilot Study of Post-Operative Adjuvant Vaccine for Advanced Gastric CancerTowards personalized perioperative treatment for advanced gastric cancer.ATF3 functions as a novel tumor suppressor with prognostic significance in esophageal squamous cell carcinoma.Transcriptional factor typing with SOX2, HNF4aP1, and CDX2 closely relates to tumor invasion and Epstein-Barr virus status in gastric cancerAssociation between changing mortality of digestive tract cancers and water pollution: a case study in the Huai River Basin, China.Current management and future strategies of gastric cancer.Efficacy of adjuvant chemotherapy combined with immunotherapy with cytokine-induced killer cells for gastric cancer after d2 gastrectomy.BET inhibition as a new strategy for the treatment of gastric cancer.MiR-451, a potential prognostic biomarker and tumor suppressor for gastric cancerThioredoxin and thioredoxin-interacting protein as prognostic markers for gastric cancer recurrence.Do Clinical and Demographic Features of Patients with Upper-Gastrointestinal Cancer Affect their Health-related Quality of Life?BC200 LncRNA a potential predictive marker of poor prognosis in esophageal squamous cell carcinoma patientsAssociations between variants of the 8q24 chromosome and nine smoking-related cancer sitesExpression of connective tissue growth factor in tumor tissues is an independent predictor of poor prognosis in patients with gastric cancerMeta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer.Overexpression of Endoplasmic Reticulum Oxidoreductin 1-α (ERO1L) Is Associated with Poor Prognosis of Gastric Cancer.MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of NF-κB signaling.Tissue engineered scaffolds for an effective healing and regeneration: reviewing orthotopic studies.A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models.Upregulation of microRNA-375 increases the cisplatin-sensitivity of human gastric cancer cells by regulating ERBB2.Effect of doxorubicin, oxaliplatin, and methotrexate administration on the transcriptional activity of BCL-2 family gene members in stomach cancer cells.The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents.Decreased expression of CIAPIN1 is correlated with poor prognosis in patients with esophageal squamous cell carcinoma.Macrophage migration inhibitory factor regulates proliferation of gastric cancer cells via the PI3K/Akt pathway.The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.Suppression of C-myc expression associates with anti-proliferation of aloe-emodin on gastric cancer cells.Assessment of health-related quality of life of patients with esophageal squamous cell carcinoma following esophagectomy using EORTC quality of life questionnaires.The optimal chemotherapeutic regimen in D2-resected locally advanced gastric cancer: a propensity score-matched analysis.Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy.Monitoring with sensitive tumor markers contributes to decision-making and better prognosis in gastric cancer patients with peritoneal recurrence.A novel therapeutic strategy with anti-CD9 antibody in gastric cancers.Venous invasion as a risk factor for recurrence after gastrectomy followed by chemotherapy for stage III gastric cancer.Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.Tissue engineered esophagus by copper--small intestinal submucosa graft for esophageal repair in a canine model.Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI).
P2860
Q24202957-BDF2BA57-20EE-4255-A1EA-1578235B45ACQ24241264-36F0CFFD-59AA-45DF-94B0-29C4FE72EC42Q27026877-3E9DEAD2-6C57-4F97-AF62-09BB873DC2EFQ28394311-98B751BC-807B-46EF-869E-DCC1109DDD3BQ33420251-ECFD90A3-CA5D-4249-8878-CAB6FDE7A0EDQ33885978-9D665213-C08A-4967-AC5A-972E53BE6219Q34137285-554E1032-FA86-4135-B3A9-B027EEBF30E7Q34483678-4B9ACA98-1354-419A-9E2E-D5AEECA93097Q34766905-65F7DBB3-ACEC-4EE2-BF9E-C095CDEEA0B9Q35015034-0D5E69FE-015F-4EB0-8180-199E9A045F0AQ35767395-A6D84D2F-61D0-454F-8D23-330E3124D39BQ35870886-2D0A99F1-7661-4543-8BCC-4D849B8BDF6FQ36040347-1DD559CA-CA78-48A5-BDB7-C3CE4B624506Q36095191-EEB4D9E2-3F47-4974-B2F4-08EE098DB032Q36351914-4F2AE7D3-8ED5-47D1-98A1-F01B71CEB8D3Q36422644-A88D9BD7-19C1-4EF6-847D-9A67D5488BB8Q36838825-E586163F-4642-4544-90CA-E5A386767757Q37146970-126340F7-2A48-4256-B1FE-5034DB4C7835Q37240441-812716E4-E85C-47F7-89DB-85A823DBDC0FQ37328181-2AE55834-168D-4FBB-B1D9-58BF87803D9DQ37367455-153544AC-F297-48E8-8B2E-262FA9AF95E7Q37562273-3E2C2AD0-0C01-446F-919C-82236CEF121DQ38253653-1E592322-A13A-416C-AA3B-848633D0F77DQ38477495-7C8FA315-E488-4980-B361-A3A3FEAA4D08Q38792755-9B632A49-01FF-476A-BD4E-738B85A09130Q39136321-EC97041C-A189-4281-9D25-588A3D40914EQ39558472-850CF8F9-8CAC-48BB-AA4D-56DCB518FE90Q39711957-A8A883FB-3323-4631-9FA5-AF296ABC755FQ39770702-22DFA55A-0943-4933-B3A1-5DBCB10B5E33Q39836423-BF5D785F-36A8-4B4E-9785-D635238459CCQ39987298-6F750097-EB2E-4EBF-8B4F-345674A6FD2FQ41981466-24CCEB55-BDAD-419A-9BF8-E51C8A017B0FQ42371668-AB92F2BA-26BF-45F7-8379-70A0C25BC791Q42685325-AA02A15F-9967-4752-BD74-7C03CA40A5DEQ47376379-0DC9DFE2-73B8-41C1-BEC7-D1847C7E1F5BQ47727915-1DC31DCA-D2DF-48F5-AB42-2B74BAC4E430Q49394503-4880C4E6-54FC-4DF9-8040-65CB9BAA5CADQ53559950-8A4E9505-7375-4667-902F-FC82CED6B8BCQ53636540-A83B23AC-8F6F-4057-94F4-256ACE948854Q55005321-80B586BD-2A3D-4A16-92DF-FEDDE289E6DF
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Updates on esophageal and gastric cancers.
@ast
Updates on esophageal and gastric cancers.
@en
type
label
Updates on esophageal and gastric cancers.
@ast
Updates on esophageal and gastric cancers.
@en
prefLabel
Updates on esophageal and gastric cancers.
@ast
Updates on esophageal and gastric cancers.
@en
P2860
P356
P1476
Updates on esophageal and gastric cancers.
@en
P2093
Charles Cha
P2860
P304
P356
10.3748/WJG.V12.I20.3237
P407
P577
2006-05-01T00:00:00Z